Skip to main content
Evidence Snapshot

Endothelin receptor type B

CHEMBL1785 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1785
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Endothelin receptor type B as ChEMBL target CHEMBL1785, mapped to UniProt P24530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Endothelin receptor type B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1785
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24530
Endothelin receptor type B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Endothelin receptor type B matters

As of 2026-09-13

Endothelin receptor type B is reviewed as Endothelin receptor type B (UniProt P24530); Endothelin receptor type B shows late clinical disease relevance led by heart failure. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 1746 compounds, and 239 assays, with lead potency reaching pChEMBL 10.8.

Disease context
heart failure

Endothelin receptor type B shows late clinical disease relevance led by heart failure. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include TEZOSENTAN.

Start review with heart failure because it currently carries late clinical support. Linked drugs include TEZOSENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 1746 compounds, and 239 assays for this target. The dominant activity type is IC50. CHEMBL1790180 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL1790180 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Endothelin receptor type B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24530, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why heart failure is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1746
Total Compounds
239
Total Assays
7
Approved Drugs
IC50: 1278.0, KI: 215.0, EC50: 2.0, KD: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1790180
 10.8 Ki —
No preferred name
CHEMBL1790180
 10.5 IC50 —
No preferred name
CHEMBL437472
 10.2 Ki Clinical
No preferred name
CHEMBL3980643
 10.0 IC50 —
No preferred name
CHEMBL437472
 9.9 IC50 Clinical

Approved Drugs

Structure Compound First Approval
APROCITENTAN
CHEMBL2165326
 2024
MACITENTAN
CHEMBL2103873
 2010
AMBRISENTAN
CHEMBL1111
 2007
BOSENTAN
CHEMBL957
 2001
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1785